Ads
related to: pfizer covid vaccine wiki
Search results
Results From The WOW.Com Content Network
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
How COVID‑19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect. Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States.The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
Two of the first approved vaccines, Pfizer and BioNTech's Pfizer-BioNTech COVID‑19 vaccine and Moderna's mRNA-1273, must be kept cold during transport. Keeping the temperatures sufficiently low is accomplished with specially-designed containers [ a ] and dry ice , but dry ice is only allowed in limited quantities on airplanes as the gases ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [37] is an mRNA vaccine [156] produced by the German company BioNTech and the American company Pfizer. [ 156 ] [ 157 ] [ 158 ] In Hong Kong, Macau, and Taiwan, Comirnaty is distributed by Fosun Pharma .
There are now more than 50 cases of the new coronavirus variant here in the U.S., according to the CDC. Most of the U.S. cases are in California and Florida. Colorado has at least two cases, and ...
On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19. [128] The efficacy was updated to 95% a week later. [129] Akiko Iwasaki, an immunologist interviewed by The New York Times, described the efficacy figure as "really a spectacular number."
By 5 January 2021, 1.3 million people across the UK had received their first dose of either the Pfizer or Oxford–AstraZeneca COVID-19 vaccine, which included more than 650,000 people over 80, representing around 23% of that age band in England. [116]